scholarly journals A prize-collecting Steiner tree application for signature selection to stratify diffuse large B-cell lymphoma subtypes

2018 ◽  
Author(s):  
Murodzhon Akhmedov ◽  
Luca Galbusera ◽  
Roberto Montemanni ◽  
Francesco Bertoni ◽  
Ivo Kwee

ABSTRACTBackground:With the explosion of high-throughput data available in biology, the bottleneck is shifted to effective data interpretation. By taking advantage of the available data, it is possible to identify the biomarkers and signatures to distinguish subtypes of a specific cancer in the context of clinical trials. This requires sophisticated methods to retrieve the information out of the data, and various algorithms have been recently devised.Results:Here, we applied the prize-collecting Steiner tree (PCST) approach to obtain a gene expression signature for the classification of diffuse large B-cell lymphoma (DLBCL). The PCST is a network-based approach to capture new insights about genomic data by incorporating an interaction network landscape. Moreover, we adopted the ElasticNet incorporating PCA as a classification method. We used seven public gene expression profiling datasets (three for training, and four for testing) available in the literature, and obtained 10 genes as signature. We tested these genes by employing ElasticNet, and compared the performance with the DAC algorithm as current golden standard. The performance of the PCST signature with ElasticNet outperformed the DAC in distinguishing the subtypes. In addition, the gene expression signature was able to accurately stratify DLBCL patients on survival data.Conclusions:We developed a network-based optimization technique that performs unbiased signature selection by integrating genomic data with biological networks. Our classifier trained with the obtained signature outperformed the state-of-the-art method in subtype distinction and survival data stratification in DLBCL. The proposed method is a general approach that can be applied on other classification problems.

Blood ◽  
2013 ◽  
Vol 121 (1) ◽  
pp. 156-158 ◽  
Author(s):  
Fangxin Hong ◽  
Brad S. Kahl ◽  
Robert Gray

Abstract Multiple gene expression–based signatures have been identified in diffuse large B-cell lymphoma that are predictive for survival outcomes. Most studies assess predictive significance based on P values from multivariable Cox regression. Few investigations have evaluated the incremental usefulness of these signatures. Recent developments in statistical methodology extend the use of concordance measures on censored survival data. We applied these methods to evaluate the added value in survival risk prediction from 3 published gene-based signatures on 2 sets of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. Our results indicate these gene-based signatures are inferior to clinical factors and provide little added value in risk assessment. To develop highly discriminating risk prediction models, we need to use appropriate approaches and consider more than gene expression. However, the study of gene expression and clinical outcomes retains considerable potential to enhance understanding of disease mechanisms and uncover new therapeutic targets.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Selin Merdan ◽  
Kritika Subramanian ◽  
Turgay Ayer ◽  
Johan Van Weyenbergh ◽  
Andres Chang ◽  
...  

AbstractThe clinical risk stratification of diffuse large B-cell lymphoma (DLBCL) relies on the International Prognostic Index (IPI) for the identification of high-risk disease. Recent studies suggest that the immune microenvironment plays a role in treatment response prediction and survival in DLBCL. This study developed a risk prediction model and evaluated the model’s biological implications in association with the estimated profiles of immune infiltration. Gene-expression profiling of 718 patients with DLBCL was done, for which RNA sequencing data and clinical covariates were obtained from Reddy et al. (2017). Using unsupervised and supervised machine learning methods to identify survival-associated gene signatures, a multivariable model of survival was constructed. Tumor-infiltrating immune cell compositions were enumerated using CIBERSORT deconvolution analysis. A four gene-signature-based score was developed that separated patients into high- and low-risk groups. The combination of the gene-expression-based score with the IPI improved the discrimination on the validation and complete sets. The gene signatures were successfully validated with the deconvolution output. Correlating the deconvolution findings with the gene signatures and risk score, CD8+ T-cells and naïve CD4+ T-cells were associated with favorable prognosis. By analyzing the gene-expression data with a systematic approach, a risk prediction model that outperforms the existing risk assessment methods was developed and validated.


2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Ying Huang ◽  
Sheng Ye ◽  
Yabing Cao ◽  
Zhiming Li ◽  
Jiajia Huang ◽  
...  

Diffuse large B-cell lymphoma (DLBCL) can be molecularly subtyped as either germinal center B-cell (GCB) or non-GCB. The role of rituximab(R) in these two groups remains unclear. We studied 204 patients with de novo DLBCL (107 treated with first-line CHOP; 97 treated with first-line R-CHOP), patients being stratified into GCB and non-GCB on the basis of BCL-6, CD10, and MUM1 protein expression. The relationships between clinical characteristics, survival data, and immunophenotype (IHC) were studied. The 5-year overall survival (OS) in the CHOP and R-CHOP groups was 50.4% and 66.6% (P=0.031), respectively. GCB patients had a better 5-year OS than non-GCB patients whether treated with CHOP or not (65.0% versus 40.9%;P=0.011). In contrast, there is no difference in the 5-year OS for the GCB and non-GCB with R-CHOP (76.5% versus 61.3%;P=0.141). In non-GCB subtype, additional rituximab improved survival better than CHOP (61.3% versus 40.9%;P=0.0303). These results indicated that addition of rituximab to standard chemotherapy eliminates the prognostic value of IHC-defined GCB and non-GCB phenotypes in DLBCL by improving the prognostic value of non-GCB subtype of DLBCL.


Sign in / Sign up

Export Citation Format

Share Document